REPLIMUNE GROUP INC (REPL) Stock Price & Overview
NASDAQ:REPL • US76029N1063
Current stock price
The current stock price of REPL is 1.86 USD. Today REPL is down by -10.14%. In the past month the price decreased by -73.35%. In the past year, price decreased by -79.45%.
REPL Key Statistics
- Market Cap
- 153.58M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.44
- Dividend Yield
- N/A
REPL Stock Performance
REPL Stock Chart
REPL Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to REPL. When comparing the yearly performance of all stocks, REPL is a bad performer in the overall market: 98.96% of all stocks are doing better.
REPL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to REPL. REPL has a bad profitability rating. Also its financial health evaluation is rather negative.
REPL Earnings
REPL Forecast & Estimates
14 analysts have analysed REPL and the average price target is 12.58 USD. This implies a price increase of 576.16% is expected in the next year compared to the current price of 1.86.
For the next year, analysts expect an EPS growth of -12.08% and a revenue growth -100% for REPL
REPL Groups
Sector & Classification
REPL Financial Highlights
Over the last trailing twelve months REPL reported a non-GAAP Earnings per Share(EPS) of -3.44. The EPS decreased by -12.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.38% | ||
| ROE | -149.55% | ||
| Debt/Equity | 0.33 |
REPL Ownership
REPL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.808B | ||
| AMGN | AMGEN INC | 15.1 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.53 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About REPL
Company Profile
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Company Info
IPO: 2018-07-20
REPLIMUNE GROUP INC
500 Unicorn Park Dr
Woburn MASSACHUSETTS 01801 US
CEO: Philip Astley-Sparke
Employees: 479
Phone: 17812229600
REPLIMUNE GROUP INC / REPL FAQ
What does REPL do?
Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
What is the current price of REPL stock?
The current stock price of REPL is 1.86 USD. The price decreased by -10.14% in the last trading session.
Does REPLIMUNE GROUP INC pay dividends?
REPL does not pay a dividend.
What is the ChartMill technical and fundamental rating of REPL stock?
REPL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the growth outlook for REPLIMUNE GROUP INC?
The Revenue of REPLIMUNE GROUP INC (REPL) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns REPLIMUNE GROUP INC?
You can find the ownership structure of REPLIMUNE GROUP INC (REPL) on the Ownership tab.
What is the Short Interest ratio of REPLIMUNE GROUP INC (REPL) stock?
The outstanding short interest for REPLIMUNE GROUP INC (REPL) is 20.24% of its float.